title: The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of adding a low-dose oral desmopressin to tamsulosin therapy for treatment of nocturia in patients with benign prostatic hyperplasia (BPH).
  
  
  METHODS
  Eligible patients with BPH and nocturia ≥2/night were randomly allocated to two treatment groups; the first of which received 3-month treatment scheme of daily oral dose of tamsulosin OCAS 0.4 mg and desmopressin MELT 60 mcg (D/T group), while the second one received tamsulosin OCAS 0.4 mg only (T group). Patients were followed on monthly basis and changes in the parameters from baseline to 3 months after treatment were assessed on I-PSS/QoL questionnaire, 7-day voiding diary, urinalysis, serum sodium, abdominal ultrasonography and uroflowmetry.
  
  
  RESULTS
  A total of 248 patients were included within the study; 123 patients in the combined D/T group and 125 patients in T group. The frequencies of night voids decreased by 64.3% in D/T group compared to 44.6% in T group. The first sleep period, significantly increased from 82.1 to 160.0 min and from 83.2 to 123.8 min in D/T and T group, respectively; and significant differences between both groups were observed at the end of study (p < 0.001). I-PSS, QoL score, post-void residual urine volume and Q max were significantly improved with no statistical difference between both groups. No serious adverse effects were reported in both groups.
  
  
  CONCLUSIONS
  The addition of low-dose oral desmopressin therapy to an α-blocker tamsulosin provides effective treatment for nocturia in patients with LUTS/BPH.
authors.affiliation: Department of Urology, Faculty of Medicine, Al-Azhar University, Nasr City, Cairo, 11884, Egypt, abulfotouhahmed@yahoo.com.
authors.forename: Abul-Fotouh
authors.initials: AF
authors.lastname: Ahmed
authors.forename: Aref
authors.initials: A
authors.lastname: Maarouf
authors.forename: Essam
authors.initials: E
authors.lastname: Shalaby
authors.forename: Ahmad H
authors.initials: AH
authors.lastname: Gabr
authors.forename: Ashraf
authors.initials: A
authors.lastname: Shahin
authors.forename: Ammar
authors.initials: A
authors.lastname: Ghobish
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D050034:Antidiuretic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D053158:Nocturia / Q000188:drug therapy* / Q000209:etiology*; D011470:Prostatic Hyperplasia / Q000150:complications*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome; D014556:Urine; D064804:Urological Agents / Q000627:therapeutic use
chemical_list: D050034:Antidiuretic Agents; D013449:Sulfonamides; D064804:Urological Agents; D003894:Deamino Arginine Vasopressin; D000077409:Tamsulosin